Ying Ye
Celgene
20 Papers
33 Citations
Ying Ye is an academic researcher from Celgene. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 5, co-authored 12 publications.
Chat about Author
Papers
Pharmacokinetics and pharmacodynamics of nab-paclitaxel in patients with solid tumors: Disposition kinetics and pharmacology distinct from solvent-based paclitaxel
TL;DR: At a given exposure level, neutropenia development was positively correlated with increasing age but not significantly influenced by hepatic function, tumor type, sex, or dosing schedule, which supports exposure‐matched dose adjustments in patients with moderate to severe hepatic impairment.
108
JNK inhibition reduces lung remodeling and pulmonary fibrotic systemic markers
Jos van der Velden,Ying Ye,James D. Nolin,Sidra M. Hoffman,David G. Chapman,Karolyn G. Lahue,Sarah Abdalla,Peng Chen,Yong Liu,Brydon L. Bennett,Nasreen Khalil,Donna Sutherland,William T. Smith,Gerald Horan,Mahmoud Assaf,Zebulun Horowitz,Rajesh Chopra,R. Stevens,Maria Palmisano,Yvonne M. W. Janssen-Heininger,Peter H. Schafer +20 more
TL;DR: Results illustrate JNK enzymatic activity involvement during pulmonary fibrosis, and support systemic biomarker use for tracking disease progression and the potential clinical benefit of this novel intervention in IPF.
Phase 2 Trial of Iberdomide in Systemic Lupus Erythematosus.
Joan T. Merrill,Victoria P. Werth,Richard Furie,Ronald F van Vollenhoven,Thomas Dörner,Milan Petronijevic,Jorge Velasco,Maria Majdan,Fedra Irazoque-Palazuelos,Michael Weiswasser,S Korish,Ying Ye,Allison Gaudy,Peter H. Schafer,Zhaohui Liu,N. K. Agafonova,N. Delev +16 more
TL;DR: In this 24-week, phase 2 trial involving patients with SLE, iberdomide at a dose of 0.45 mg resulted in a higher percentage of patients with an SRI-4 response than did placebo, with no significant differences between the groups that received the lower doses of iberDomide and the group that received placebo.
37
Protective effect of quercetin on cadmium-induced renal apoptosis through cyt-c/caspase-9/caspase-3 signaling pathway
TL;DR: Cd can induce kidney injury and apoptosis of renal cells, while Que can reduce Cd-induced kidney damage by reducing oxidative stress and inhibiting apoptosis and provide a theoretical basis for the clinical application of Que in the prevention and treatment of cadmium poisoning.
Lenalidomide at Therapeutic and Supratherapeutic Doses Does Not Prolong QTc Intervals in the Thorough QTc Study Conducted in Healthy Men
Nianhang Chen,Ying Ye,Liangang Liu,Josephine Reyes,Mahmoud Assaf,Claudia Kasserra,Simon Zhou,Maria Palmisano +7 more
TL;DR: Single doses of lenalidomide up to 50 mg were not associated with prolonged QTc intervals in healthy males and the C–QTc analysis further assured that lenalidOMide doses up to50 mg are not expected to prolong QTC intervals in patients.
20